Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Soft Tissue Sarcoma
100%
Menses
100%
Follicle-stimulating Hormone
100%
Luteinizing Hormone
100%
Postoperative Adjuvant Radiotherapy
100%
Ovarian Function
100%
Postoperative Adjuvant Therapy
100%
Radiotherapy
66%
High Dose
66%
Methotrexate
66%
Women Age
66%
Gonadotropins
66%
Doxorubicin-cyclophosphamide
66%
Chemotherapy
33%
Pelvis
33%
Older Women
33%
Adjuvant Therapy
33%
Estradiol
33%
Age-related
33%
Chemotherapy Alone
33%
Radiation Dose
33%
Amenorrhea
33%
Menstrual Irregularities
33%
Ovarian Dysfunction
33%
Thigh
33%
Age at Treatment
33%
Chest Wall
33%
Medicine and Dentistry
Soft Tissue Sarcoma
100%
Adjuvant Chemotherapy
100%
Follitropin
100%
Luteinizing Hormone
100%
Adjuvant Radiotherapy
100%
Ovary Function
100%
Drug Megadose
66%
Methotrexate
66%
Cyclophosphamide
66%
Doxorubicin
66%
Gonadotropin
66%
Radiation Therapy
66%
Chemotherapy
66%
Pelvis
33%
Adjuvant Therapy
33%
Diethylstilbestrol
33%
Thoracic Wall
33%
Ovary Insufficiency
33%
Amenorrhea
33%
Menstrual Irregularity
33%
Thigh
33%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy Regimens
100%
Follitropin
100%
Luteinizing Hormone
100%
Soft Tissue Sarcoma
100%
Doxorubicin
66%
Cyclophosphamide
66%
Gonadotropin
66%
Methotrexate
66%
Diethylstilbestrol
33%
Amenorrhea
33%
Ovary Insufficiency
33%
Menstrual Irregularity
33%